Alterity Therapeutics Reports Trading Halt
Ticker: PRNAF · Form: 6-K · Filed: Jul 15, 2024 · CIK: 1131343
| Field | Detail |
|---|---|
| Company | Alterity Therapeutics Ltd (PRNAF) |
| Form Type | 6-K |
| Filed Date | Jul 15, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: trading-halt, filing-update, registration-statement
Related Tickers: ATHE
TL;DR
Alterity Therapeutics (ATHE) trading halted, likely for a major announcement.
AI Summary
Alterity Therapeutics Limited filed a Form 6-K on July 15, 2024, to report a trading halt. This filing is incorporated by reference into several of their existing Registration Statements on Form S-8 and Form F-3. The company was formerly known as Prana Biotechnology Ltd.
Why It Matters
A trading halt typically indicates that a company is about to make a significant announcement, which could impact its stock price.
Risk Assessment
Risk Level: medium — Trading halts can precede significant news, leading to increased volatility and uncertainty for investors.
Key Players & Entities
- Alterity Therapeutics Limited (company) — Registrant
- Prana Biotechnology Ltd (company) — Former company name
- Form S-8 (document) — Registration Statement
- Form F-3 (document) — Registration Statement
FAQ
What is the purpose of this Form 6-K filing?
This Form 6-K is being filed to report a trading halt by Alterity Therapeutics Limited.
When was this filing submitted?
The filing was submitted on July 15, 2024.
What is the company's principal executive office address?
The principal executive office is located at Level 14, 350 Collins Street, Melbourne, Victoria 3000, Australia.
Is Alterity Therapeutics Limited incorporating this filing into any other SEC filings?
Yes, this Form 6-K is being incorporated by reference into their Registration Statements on Form S-8 and Form F-3.
What was the company's former name?
The company was formerly known as Prana Biotechnology Ltd.
Filing Stats: 186 words · 1 min read · ~1 pages · Grade level 11.6 · Accepted 2024-07-15 06:51:19
Filing Documents
- ea0209411-6k_alterity.htm (6-K) — 14KB
- ea020941101ex99-1_alterity.htm (EX-99.1) — 10KB
- ex99-1_001.jpg (GRAPHIC) — 5KB
- ex99-1_002.jpg (GRAPHIC) — 13KB
- 0001213900-24-061159.txt ( ) — 51KB
From the Filing
OF FOREIGN PRIVATE ISSUER SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2024 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073 , 333-248980 and 333-228671 ) and our Registration Statements on Form F-3 (Files No. 333-274816 , 333-251647 , 333-231417 and 333-250076 ) ALTERITY THERAPEUTICS LIMITED (a development stage enterprise) The following exhibits are submitted: 99.1 Trading Halt 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Alterity Therapeutics Limited By: /s/ Geoffrey P. Kempler Geoffrey P. Kempler Chairman Date: July 14, 2024 2